Myka Ransom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Myka Ransom has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Sarah Tess Brown
Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
4 shared publications - Elizabeth McGinnis
Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
2 shared publications - Howard Collier
Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
2 shared publications Jane Nixon
Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
2 shared publications- Neil McHugh
Department of Life Sciences, University of Bath , Bath
2 shared publications - Philip Helliwell
P.S. Helliwell, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK
2 shared publications
Latest Publications
- Open Access
Pragmatic randomised controlled trial to evaluate the clinical and cost-effectiveness of compression therapy for surgical wounds healing by secondary intention following excision of lower limb keratinocyte cancers in UK skin cancer surgery centres (HEALS2 trial): study protocol
Introduction: Keratinocyte cancers (KCs) are increasing in incidence in the UK, with over 234 000 cases annually, largely due to demographic changes and sun exposure. Skin cancers, including malignant melanoma and KCs, are projected to cost the NHS over £180 million annually and impose healthcare demands. Although KCs have high cure rates following surgical excision and primary closure, wounds healing by secondary intention (HBSI) particularly on the lower leg present clinical challenges. Compression therapy (CT) known to improve venous insufficiency and venous ulcer healing may also benefit HBSI following lower limb KC excision but current evidence is sparse. Methods and analysis: H ealing of E xcision A l wounds on L ower legs by S econdary intention (HEALS2) is a multicentre, prospective, Phase III, parallel group, open-label, randomised controlled trial with embedded internal pilot and blinded endpoint assessment. A total of 396 participants (≥18 years) from UK skin cancer surgery centres will be randomised 1:1 to assess the clinical and cost-effectiveness of standard care (SC) alone or with CT (SC+CT) for surgical wounds HBSI following excision of lower limb KCs. The primary outcome is time to healing from randomisation (maximum 52-week follow-up). Secondary outcomes include incidence of infection, antibiotic usage, scar quality, safety (including complications and hospitalisations), quality of life, cost-effectiveness and relationship between post-partial closure wound area, type of partial closure method and time to healing. Exploratory objectives include association between short-term wound area reduction and time to HBSI, patient acceptability, adherence and associations between wound breakdown post-healing and CT use. A qualitative sub-study will explore patients’ experiences and decision-making during CT use. Primary endpoint analysis will be conducted on the intention-to-treat population using a multivariable Cox Proportional Hazards modelling. Secondary outcomes and safety will be evaluated using other regression models and descriptive statistics, respectively. Cost-effectiveness will be evaluated using within-trial analysis and decision-analytic modelling. Patient and public involvement representatives are contributing to trial design and oversight. The study protocol complies with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Statement. Ethics and dissemination: Ethics approval has been granted by the Yorkshire & The Humber – Leeds East Research Ethics Committee (ref 23/YH/0247). Findings will be published in high-impact peer-reviewed journals. Trial registration number: ISRCTN12417689 .
Open AccessPragmatic randomised controlled trial to evaluate the clinical and cost-effectiveness of compression therapy for surgical wounds healing by secondary intention following excision of lower limb keratinocyte cancers in UK skin cancer surgery centres (HEALS2 trial): study protocol
Introduction: Keratinocyte cancers (KCs) are increasing in incidence in the UK, with over 234 000 cases annually, largely due to demographic changes and sun exposure. Skin cancers, including malignant melanoma and KCs, are projected to cost the NHS over £180 million annually and impose healthcare demands. Although KCs have high cure rates following surgical excision and primary closure, wounds healing by secondary intention (HBSI) particularly on the lower leg present clinical challenges. Compression therapy (CT) known to improve venous insufficiency and venous ulcer healing may also benefit HBSI following lower limb KC excision but current evidence is sparse. Methods and analysis: H ealing of E xcision A l wounds on L ower legs by S econdary intention (HEALS2) is a multicentre, prospective, Phase III, parallel group, open-label, randomised controlled trial with embedded internal pilot and blinded endpoint assessment. A total of 396 participants (≥18 years) from UK skin cancer surgery centres will be randomised 1:1 to assess the clinical and cost-effectiveness of standard care (SC) alone or with CT (SC+CT) for surgical wounds HBSI following excision of lower limb KCs. The primary outcome is time to healing from randomisation (maximum 52-week follow-up). Secondary outcomes include incidence of infection, antibiotic usage, scar quality, safety (including complications and hospitalisations), quality of life, cost-effectiveness and relationship between post-partial closure wound area, type of partial closure method and time to healing. Exploratory objectives include association between short-term wound area reduction and time to HBSI, patient acceptability, adherence and associations between wound breakdown post-healing and CT use. A qualitative sub-study will explore patients’ experiences and decision-making during CT use. Primary endpoint analysis will be conducted on the intention-to-treat population using a multivariable Cox Proportional Hazards modelling. Secondary outcomes and safety will be evaluated using other regression models and descriptive statistics, respectively. Cost-effectiveness will be evaluated using within-trial analysis and decision-analytic modelling. Patient and public involvement representatives are contributing to trial design and oversight. The study protocol complies with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Statement. Ethics and dissemination: Ethics approval has been granted by the Yorkshire & The Humber – Leeds East Research Ethics Committee (ref 23/YH/0247). Findings will be published in high-impact peer-reviewed journals. Trial registration number: ISRCTN12417689 .
- Open Access
- 1 June 2025
- Published by National Institute for Health and Care Research in Programme Grants for Applied Research
- p. 1-56
Early detection to improve outcome in people with undiagnosed psoriatic arthritis: the PROMPT research programme including RCT
Background: Longitudinal observational studies suggest that patients who present early to secondary care with psoriatic arthritis have a better outcome. Outcome needs to be measured including domains important to patients. Objectives: To identify disease activity and impact outcomes important to patients with psoriatic arthritis in comparison to existing ones (Patient-Reported Outcome Measurement Study). To assess the validity of new measures of disease activity in psoriatic arthritis derived from patient engagement (ASSESSment of modified composite disease measures study). To explore patients’ experiences of diagnosis in psoriatic arthritis? (Experiences of screening and diaGnosis from the perspective of pAtients with PSoriasis and psoriatic arthritis study). To identify modifiable risk factors for the development of psoriatic arthritis using the Clinical Practice Research Datalink (EPIdemiology of psoriatiC arthritis study). To compare the performance of screening tools for detecting undiagnosed psoriatic arthritis (COMparison of Psoriatic Arthritis scREening tools study). To investigate the clinical effectiveness (Total bUrDen Of psoRiasis trial) and cost-effectiveness (COSt of screening for Psoriatic Arthritis study) of detecting undiagnosed psoriatic arthritis. Design and methods: Mixed methods using data from patient focus groups, a multicentre cohort study, primary care health records (Clinical Practice Research Datalink) and a prospective randomised clinical trial (Total bUrDen Of psoRiasis trial, COMparison of Psoriatic Arthritis scREening tools study, COSt of screening for Psoriatic Arthritis study). Setting and participants: Focus groups and cohort studies of 221 patients with psoriatic arthritis including newly diagnosed cases (Patient-Reported Outcome Measurement Study, ASSESSment of modified composite disease measures study, experiences of screening and diaGnosis from the perspective of pAtients with PSoriasis and psoriatic arthritis study) and 2225 patients with psoriasis from primary care not known to have psoriatic arthritis from 135 randomised general practices (COMparison of Psoriatic Arthritis scREening tools study, Total bUrDen Of psoRiasis trial randomised clinical trial, COSt of screening for Psoriatic Arthritis study). Intervention: Randomised controlled trial comparing the early identification of psoriatic arthritis by annual rheumatological assessment (enhanced surveillance) in people with psoriasis identified in primary care (n = 1123) with standard care (n = 1102). Participants with suspected inflammatory arthritis were referred to the local rheumatology clinic for an assessment of psoriatic arthritis (enhanced surveillance arm: at baseline, 12 and 24 months; standard care arm: at 24 months). Data sources: Cohort studies of incident psoriasis (n = 90,189) or psoriatic arthritis (n = 6783) patients from the Clinical Practice Research Datalink (EPIdemiology of psoriatiC arthritis study). Cost-effective analysis using data collected in Total bUrDen Of psoRiasis trial. Modelling exercise to extrapolate screening performance from Total bUrDen Of psoRiasis trial to long-term costs and quality-adjusted life-years (COSt of screening for Psoriatic Arthritis study). Main outcome measure: In Total bUrDen Of psoRiasis trial the primary outcome was the Health Assessment Questionnaire Disability Index at 24 months post registration in participants diagnosed with psoriatic arthritis. Results: Patient-Reported Outcome Measurement Study: Patients rated pain and fatigue as the most important outcomes when receiving treatment for psoriatic arthritis. ASSESSment of modified composite disease measures study: Shortened versions of visual analogue scales performed well in detecting treatment change and responsiveness over 6 months. Experiences of screening and diaGnosis from the perspective of pAtients with PSoriasis and psoriatic arthritis study: Missed opportunities for psoriatic arthritis diagnosis has implications for well-being including mental health, and there is a need for provision of psychological support and self-management guidance. Screening for psoriatic arthritis was generally regarded as a positive experience. EPIdemiology of psoriatiC arthritis study: Bayesian networks identified clusters of symptoms that can accurately predict the development of psoriatic arthritis (area under the curve 0.73, 95% CI 0.70 to 0.75). Obesity is a modifiable lifestyle factor that increases the risk of developing psoriatic arthritis and diminishes linearly over a 10-year period with a reduction in body mass index. Diabetes, cardiovascular disease, uveitis and Crohn’s disease are associated with psoriatic arthritis and may appear early in the disease course. COMparison of Psoriatic Arthritis scREening tools study: The Psoriasis Epidemiology Screening Tool questionnaire remains the preferred screening tool, given its simplicity with no significant differences in performance (sensitivity: 0.625, specificity: 0.757, area under the curve 0.787) compared to COmparisoN of ThreE Screening Tools to detect psoriatic arthritis in patients with psoriasis. Total bUrDen Of psoRiasis trial: The primary analysis population consisted of 87 participants with a positive diagnosis of psoriatic arthritis: 64 in enhanced surveillance, 23 in standard care (overall mean Health Assessment Questionnaire Disability Index score at 24 months was 0.45). The adjusted odds ratio for achieving a Health Assessment Questionnaire Disability Index score of 0 at 24 months post registration in enhanced surveillance compared to standard care was 0.64 (95% CI 0.17 to 2.38), and the adjusted odds ratio of achieving a higher (non-zero) Health Assessment Questionnaire Disability Index score at 24 months post registration in enhanced surveillance relative to standard care arm was 1.12 (95% CI 0.67 to 1.86), indicating no evidence of a difference between the two treatment groups (p = 0.6612). COSt of screening for Psoriatic Arthritis study: The within-trial cost-effectiveness analysis suggests that enhanced surveillance may be associated with higher mean quality-adjusted life-years, although the difference was very small (+0.002, 95% CI –0.03 to 0.03), and lower mean costs (−£120.54, 95% CI –£540.57 to £288.99). Using the cost-effectiveness model based on the sensitivity, specificity and the psoriatic arthritis incidence from the Total bUrDen Of psoRiasis trial, Psoriasis Epidemiology Screening Tool is the most expensive and has the highest lifetime quality-adjusted life-years with an incremental cost-effectiveness ratio of £14,964 per additional quality-adjusted life-year compared to CONTEST, CONTESTjt and no screening using a lifetime time horizon. Limitations: The Total bUrDen Of psoRiasis trial was underpowered due to a lower proportion of patients developing psoriatic arthritis than expected (87 compared to 148) and disruption to follow-up due to the coronavirus pandemic. COSt of screening for Psoriatic Arthritis study analyses were limited by the extent of missing data. Conclusion: The benefit of early detection of psoriatic arthritis in a primary care psoriasis population remains unproven. Surveillance for undiagnosed psoriatic arthritis generally detects mild cases as measured by physical function. Patients rate pain and fatigue as the most important outcomes. Future work: Five-year follow-up of Total bUrDen Of psoRiasis trial participants to investigate longer-term benefits of earlier diagnosis comparing treatment arms and to assess risk factors for psoriatic arthritis development is underway. Trial registration: This trial is registered as Current Controlled Trials ISRCTN38877516. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research programme (NIHR award ref: RP-PG-1212-20007) and is published in full in Programme Grants for Applied Research; Vol. 13, No. 6. See the NIHR Funding and Awards website for further award information.
- 1 June 2025
- Published by National Institute for Health and Care Research in Programme Grants for Applied Research
- p. 1-56
Open AccessEarly detection to improve outcome in people with undiagnosed psoriatic arthritis: the PROMPT research programme including RCT
Background: Longitudinal observational studies suggest that patients who present early to secondary care with psoriatic arthritis have a better outcome. Outcome needs to be measured including domains important to patients. Objectives: To identify disease activity and impact outcomes important to patients with psoriatic arthritis in comparison to existing ones (Patient-Reported Outcome Measurement Study). To assess the validity of new measures of disease activity in psoriatic arthritis derived from patient engagement (ASSESSment of modified composite disease measures study). To explore patients’ experiences of diagnosis in psoriatic arthritis? (Experiences of screening and diaGnosis from the perspective of pAtients with PSoriasis and psoriatic arthritis study). To identify modifiable risk factors for the development of psoriatic arthritis using the Clinical Practice Research Datalink (EPIdemiology of psoriatiC arthritis study). To compare the performance of screening tools for detecting undiagnosed psoriatic arthritis (COMparison of Psoriatic Arthritis scREening tools study). To investigate the clinical effectiveness (Total bUrDen Of psoRiasis trial) and cost-effectiveness (COSt of screening for Psoriatic Arthritis study) of detecting undiagnosed psoriatic arthritis. Design and methods: Mixed methods using data from patient focus groups, a multicentre cohort study, primary care health records (Clinical Practice Research Datalink) and a prospective randomised clinical trial (Total bUrDen Of psoRiasis trial, COMparison of Psoriatic Arthritis scREening tools study, COSt of screening for Psoriatic Arthritis study). Setting and participants: Focus groups and cohort studies of 221 patients with psoriatic arthritis including newly diagnosed cases (Patient-Reported Outcome Measurement Study, ASSESSment of modified composite disease measures study, experiences of screening and diaGnosis from the perspective of pAtients with PSoriasis and psoriatic arthritis study) and 2225 patients with psoriasis from primary care not known to have psoriatic arthritis from 135 randomised general practices (COMparison of Psoriatic Arthritis scREening tools study, Total bUrDen Of psoRiasis trial randomised clinical trial, COSt of screening for Psoriatic Arthritis study). Intervention: Randomised controlled trial comparing the early identification of psoriatic arthritis by annual rheumatological assessment (enhanced surveillance) in people with psoriasis identified in primary care (n = 1123) with standard care (n = 1102). Participants with suspected inflammatory arthritis were referred to the local rheumatology clinic for an assessment of psoriatic arthritis (enhanced surveillance arm: at baseline, 12 and 24 months; standard care arm: at 24 months). Data sources: Cohort studies of incident psoriasis (n = 90,189) or psoriatic arthritis (n = 6783) patients from the Clinical Practice Research Datalink (EPIdemiology of psoriatiC arthritis study). Cost-effective analysis using data collected in Total bUrDen Of psoRiasis trial. Modelling exercise to extrapolate screening performance from Total bUrDen Of psoRiasis trial to long-term costs and quality-adjusted life-years (COSt of screening for Psoriatic Arthritis study). Main outcome measure: In Total bUrDen Of psoRiasis trial the primary outcome was the Health Assessment Questionnaire Disability Index at 24 months post registration in participants diagnosed with psoriatic arthritis. Results: Patient-Reported Outcome Measurement Study: Patients rated pain and fatigue as the most important outcomes when receiving treatment for psoriatic arthritis. ASSESSment of modified composite disease measures study: Shortened versions of visual analogue scales performed well in detecting treatment change and responsiveness over 6 months. Experiences of screening and diaGnosis from the perspective of pAtients with PSoriasis and psoriatic arthritis study: Missed opportunities for psoriatic arthritis diagnosis has implications for well-being including mental health, and there is a need for provision of psychological support and self-management guidance. Screening for psoriatic arthritis was generally regarded as a positive experience. EPIdemiology of psoriatiC arthritis study: Bayesian networks identified clusters of symptoms that can accurately predict the development of psoriatic arthritis (area under the curve 0.73, 95% CI 0.70 to 0.75). Obesity is a modifiable lifestyle factor that increases the risk of developing psoriatic arthritis and diminishes linearly over a 10-year period with a reduction in body mass index. Diabetes, cardiovascular disease, uveitis and Crohn’s disease are associated with psoriatic arthritis and may appear early in the disease course. COMparison of Psoriatic Arthritis scREening tools study: The Psoriasis Epidemiology Screening Tool questionnaire remains the preferred screening tool, given its simplicity with no significant differences in performance (sensitivity: 0.625, specificity: 0.757, area under the curve 0.787) compared to COmparisoN of ThreE Screening Tools to detect psoriatic arthritis in patients with psoriasis. Total bUrDen Of psoRiasis trial: The primary analysis population consisted of 87 participants with a positive diagnosis of psoriatic arthritis: 64 in enhanced surveillance, 23 in standard care (overall mean Health Assessment Questionnaire Disability Index score at 24 months was 0.45). The adjusted odds ratio for achieving a Health Assessment Questionnaire Disability Index score of 0 at 24 months post registration in enhanced surveillance compared to standard care was 0.64 (95% CI 0.17 to 2.38), and the adjusted odds ratio of achieving a higher (non-zero) Health Assessment Questionnaire Disability Index score at 24 months post registration in enhanced surveillance relative to standard care arm was 1.12 (95% CI 0.67 to 1.86), indicating no evidence of a difference between the two treatment groups (p = 0.6612). COSt of screening for Psoriatic Arthritis study: The within-trial cost-effectiveness analysis suggests that enhanced surveillance may be associated with higher mean quality-adjusted life-years, although the difference was very small (+0.002, 95% CI –0.03 to 0.03), and lower mean costs (−£120.54, 95% CI –£540.57 to £288.99). Using the cost-effectiveness model based on the sensitivity, specificity and the psoriatic arthritis incidence from the Total bUrDen Of psoRiasis trial, Psoriasis Epidemiology Screening Tool is the most expensive and has the highest lifetime quality-adjusted life-years with an incremental cost-effectiveness ratio of £14,964 per additional quality-adjusted life-year compared to CONTEST, CONTESTjt and no screening using a lifetime time horizon. Limitations: The Total bUrDen Of psoRiasis trial was underpowered due to a lower proportion of patients developing psoriatic arthritis than expected (87 compared to 148) and disruption to follow-up due to the coronavirus pandemic. COSt of screening for Psoriatic Arthritis study analyses were limited by the extent of missing data. Conclusion: The benefit of early detection of psoriatic arthritis in a primary care psoriasis population remains unproven. Surveillance for undiagnosed psoriatic arthritis generally detects mild cases as measured by physical function. Patients rate pain and fatigue as the most important outcomes. Future work: Five-year follow-up of Total bUrDen Of psoRiasis trial participants to investigate longer-term benefits of earlier diagnosis comparing treatment arms and to assess risk factors for psoriatic arthritis development is underway. Trial registration: This trial is registered as Current Controlled Trials ISRCTN38877516. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research programme (NIHR award ref: RP-PG-1212-20007) and is published in full in Programme Grants for Applied Research; Vol. 13, No. 6. See the NIHR Funding and Awards website for further award information.
- Open Access
Diabetic foot ulcer photography study: a study within a trial to assess the reliability of two-dimensional (2D) photography for the assessment of ulcer healing in patients with diabetes-related foot ulcers—protocol paper
Background The primary endpoint in diabetes-related foot ulcer (DFU) trials is often time to healing, defined as complete re-epithelialisation with absence of drainage, requiring clinical expert assessment as the gold standard. Central blinded photograph review for confirmation of healing is increasingly being undertaken for internal validity. The Diabetic Foot Ulcer Photography study aims to determine the agreement between blinded independent review panel members for assessing ulcer healing status in patients with DFUs. Methods and analysis Photographs of ulcers clinically assessed as healed or not healed across 300 participants recruited to one of two randomised controlled trials (MIDFUT and CODIFI2), will be independently reviewed by a central blinded panel consisting of four clinicians with expertise in ulcer healing assessment. Staff at recruiting sites will take photographs using a standardised camera and protocol. Photographs will be reviewed at three levels of magnification: raw image, image standardised to a measurement scale included in the photograph and standardised image with magnification permitted. Reviewers will assess the healing status and their confidence level in making a healing judgement, with reasons reported for a low confidence rating. Analysis at each level of magnification will estimate inter- and intra-rater reliability on the assessments of healing of photographs with the clinical assessment (primary) and confidence rating using multivariable logistic mixed models. Analysis of the learning curve for the assessment of healing and confidence rating will use exponential and two-phase models. Ethics and dissemination Ethics approval has been granted by the National Research Ethics Service Committees (MIDFUT 17/YH/0055; CODIFI2 18-WS-0235). All participants will provide a written informed consent for photography before recruited onto the respective study. Photographs will be transferred to the trials’ coordinating centre via a secure file transfer service and saved in a restricted access folder on a secure server. Results will be disseminated via publications in scientific journals and conference presentations. Trial registration number MIDFUT (ISRCTN64926597) and CODIFI2 (ISRCTN74929588).
Open AccessDiabetic foot ulcer photography study: a study within a trial to assess the reliability of two-dimensional (2D) photography for the assessment of ulcer healing in patients with diabetes-related foot ulcers—protocol paper
Background The primary endpoint in diabetes-related foot ulcer (DFU) trials is often time to healing, defined as complete re-epithelialisation with absence of drainage, requiring clinical expert assessment as the gold standard. Central blinded photograph review for confirmation of healing is increasingly being undertaken for internal validity. The Diabetic Foot Ulcer Photography study aims to determine the agreement between blinded independent review panel members for assessing ulcer healing status in patients with DFUs. Methods and analysis Photographs of ulcers clinically assessed as healed or not healed across 300 participants recruited to one of two randomised controlled trials (MIDFUT and CODIFI2), will be independently reviewed by a central blinded panel consisting of four clinicians with expertise in ulcer healing assessment. Staff at recruiting sites will take photographs using a standardised camera and protocol. Photographs will be reviewed at three levels of magnification: raw image, image standardised to a measurement scale included in the photograph and standardised image with magnification permitted. Reviewers will assess the healing status and their confidence level in making a healing judgement, with reasons reported for a low confidence rating. Analysis at each level of magnification will estimate inter- and intra-rater reliability on the assessments of healing of photographs with the clinical assessment (primary) and confidence rating using multivariable logistic mixed models. Analysis of the learning curve for the assessment of healing and confidence rating will use exponential and two-phase models. Ethics and dissemination Ethics approval has been granted by the National Research Ethics Service Committees (MIDFUT 17/YH/0055; CODIFI2 18-WS-0235). All participants will provide a written informed consent for photography before recruited onto the respective study. Photographs will be transferred to the trials’ coordinating centre via a secure file transfer service and saved in a restricted access folder on a secure server. Results will be disseminated via publications in scientific journals and conference presentations. Trial registration number MIDFUT (ISRCTN64926597) and CODIFI2 (ISRCTN74929588).
- 1 September 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (11) , 1092-1095
Incidence of Psoriatic Arthritis in a Primary Care Psoriasis Population in the United Kingdom
Objective: To determine the annual incidence of psoriatic arthritis (PsA) in a United Kingdom primary care population with preexisting psoriasis (PsO) followed prospectively over 2 years after excluding baseline prevalence of existing disease. Methods: Total Burden of Psoriasis (TUDOR; ISRCTN registry: ISRCTN38877516) was a multicenter, prospective, 2-arm parallel-group cluster randomized controlled trial of the early identification of PsA by annual rheumatological assessment (termed “Enhanced Surveillance”) vs standard care in people with PsO identified in primary care. Incidence of PsA is reported at 12 months and 24 months using patients from the Enhanced Surveillance arm, which allows for the exclusion of patients with prevalent PsA at baseline. Results: Fourteen of 511 participants attending a 12-month screen developed PsA over that interval, giving an incidence of 2.74/100 patient-years (PYs; 95% CI 1.32-4.16). Another 7/444 participants attending the 24-month visit developed PsA, giving an incidence of 1.58/100 PYs (95% CI 0.42-2.74). The combined incidence over 2 years was 2.20/100 PYs (95% CI 1.27-3.13). Conclusion: The estimated annual incidence of PsA over a 2-year period was 2.20/100 PYs, which is in keeping with studies including clinical assessment rather than relying on health records alone. Extended follow-up of the TUDOR cohort with accrual of larger numbers of incident cases will allow risk factors for PsA to be explored in more depth.
- 1 September 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (11) , 1092-1095
Incidence of Psoriatic Arthritis in a Primary Care Psoriasis Population in the United Kingdom
Objective: To determine the annual incidence of psoriatic arthritis (PsA) in a United Kingdom primary care population with preexisting psoriasis (PsO) followed prospectively over 2 years after excluding baseline prevalence of existing disease. Methods: Total Burden of Psoriasis (TUDOR; ISRCTN registry: ISRCTN38877516) was a multicenter, prospective, 2-arm parallel-group cluster randomized controlled trial of the early identification of PsA by annual rheumatological assessment (termed “Enhanced Surveillance”) vs standard care in people with PsO identified in primary care. Incidence of PsA is reported at 12 months and 24 months using patients from the Enhanced Surveillance arm, which allows for the exclusion of patients with prevalent PsA at baseline. Results: Fourteen of 511 participants attending a 12-month screen developed PsA over that interval, giving an incidence of 2.74/100 patient-years (PYs; 95% CI 1.32-4.16). Another 7/444 participants attending the 24-month visit developed PsA, giving an incidence of 1.58/100 PYs (95% CI 0.42-2.74). The combined incidence over 2 years was 2.20/100 PYs (95% CI 1.27-3.13). Conclusion: The estimated annual incidence of PsA over a 2-year period was 2.20/100 PYs, which is in keeping with studies including clinical assessment rather than relying on health records alone. Extended follow-up of the TUDOR cohort with accrual of larger numbers of incident cases will allow risk factors for PsA to be explored in more depth.